Tobam Has $210,000 Stake in Danaher Co. (NYSE:DHR)

Tobam reduced its holdings in Danaher Co. (NYSE:DHR) by 26.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 915 shares of the conglomerate’s stock after selling 325 shares during the period. Tobam’s holdings in Danaher were worth $210,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of DHR. FMR LLC increased its holdings in Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock valued at $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares during the period. International Assets Investment Management LLC increased its stake in shares of Danaher by 40,196.5% in the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock valued at $119,539,000 after acquiring an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. raised its position in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after acquiring an additional 397,671 shares during the period. Finally, Union Bancaire Privee UBP SA bought a new position in Danaher during the 4th quarter worth approximately $74,551,000. 79.05% of the stock is owned by institutional investors.

Danaher Price Performance

Shares of NYSE DHR opened at $206.92 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The business has a 50-day moving average of $233.38 and a 200-day moving average of $252.10. The stock has a market capitalization of $149.45 billion, a price-to-earnings ratio of 39.19, a PEG ratio of 2.80 and a beta of 0.83. Danaher Co. has a fifty-two week low of $205.79 and a fifty-two week high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the prior year, the business earned $2.09 earnings per share. As a group, sell-side analysts predict that Danaher Co. will post 7.77 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend was Friday, December 27th. Danaher’s dividend payout ratio (DPR) is currently 20.45%.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Stephens reiterated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a report on Wednesday, October 23rd. Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective on the stock in a research note on Thursday, October 31st. Citigroup decreased their target price on Danaher from $285.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Robert W. Baird dropped their price target on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Finally, KeyCorp lifted their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Danaher has an average rating of “Moderate Buy” and an average price target of $278.00.

Insider Buying and Selling at Danaher

In other news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.